依立替康联合卡铂方案治疗复治的小细胞肺癌临床观察.docxVIP

依立替康联合卡钳方案治疗复治的 小细胞肺癌临床观察 【摘要】 目的依立替康在SCLC 的化疗中有较好的疗效， 本试验旨在观察依 立替康联合卡钳(IC)方案二线或三线治疗 SCLC勺疗效和毒副作用。方法 11例SCLC 患者接受IC方案二线或三线化疗，评价疗 效及毒副作用。结果全组中位生存期8个 月，临床获益率％有效率％完全缓解率0% 全组山度加W度白细胞下降率 ％中性粒细 胞下降率％血小板减少率％贫血发生率0； I度加n度腹泻发生率 ％ m度加iv度腹泻 发生率0, I度加n度肝功能损害的发生率 ％ m度加w度肝功能损害的发生率 0。结论 IC方案是治疗复治的 SCLC的有效方案，IC 方案引起的迟发性腹泻是可以控制的。 【关键词】依立替康卡钳癌小细胞 [Abstract 】Objective Irinotecan is effective for the treatment of small cell lung cancer (SCLC) . The objective of this trial is to assess the efficacy and toxicity of combined chemotherapy regimen of irinotecan plus carboplatin (IC) in the second line or thirdly treatment of SCLC. Methods A clinical trial including 11 patients was conducted in which the IC regimen was the second-line or third-line regimen for the treatment of patients with SCLC. All patients were given more than two chemotherapy cycles if the regimen is effective. Results The median survival time was eight clinical response rate was %. The overall response rate was %.The complete response rate was 0%.Grade 3-4 of myelosuppressions such as leucopenia , neutropenia, thrombocytopenia and anemia were %,%,% and 0%. Grade 1-2 of diarrhea %and grade 3-4 of diarrhea was 0%. Grade 1-2 of impairment of liver function is % and grade 3-4 of impairment of liver function is 0%. Conclusion IC regimen is an effective regimen for relapse SCLC. The delayed diarrhea induced by irinotecan can be controlled by appropriate treatment . 【Key words 】Irinotecan Carboplatin Small cell lung cancer 为评价依立替康(irinotecan , CPT-11) 加卡钳(IC)方案治疗复治的小细胞肺癌 (small cell lung cancer , SCLC)的疗效 与毒副作用，本科于2006年2月至2007年 8月对11例复治的SCLC愚者给予IC方案化 疗，现将结果报告如下。 1资料与方法 一般资料11例均经病理学确诊的复治 的SCLC患者，男10例，女1例，年龄40? 66岁(中位年龄52岁)；KPS评分＞70分； 化疗前心电图及血象、肝肾功能均正常，预 计生存期2个月。所有患者均曾接受过足叶 乙贰加顺钳或类似方案治疗。IC方案作为二 线治疗的9例，其中足叶乙鼠加顺钳一线化 疗后无效或3个月内复发4例，3个月后进 展3例，艾素加奥沙利钳一线化疗后无效 1 例，足叶乙甫加卡钳一线化疗后无效 1例。 IC方案作为三线治疗的2例，1例为足叶乙 贰加顺钳一线化疗后进展，足叶乙贰加顺钳 再加异环磷酰胺二线化疗后 3个月后进展， 另1例为足叶乙玳加顺钳一线化疗后进展， 依立替康加顺钳二线化疗后无效。 治疗方法 CPT-11 65 mg/m2第1、8天, 静脉滴注，卡钳按 AUg 5计算，在第1天 使用，静脉滴注，